According to the Shiyao Innovation announcement, the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., recently received the SYS6062 “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and will conduct clinical trials in the near future. SYS6062 is an injection, a class 1 biological product for therapeutic use. It is a monoclonal antibody conjugate drug. The approved indication is advanced solid tumors. The drug still needs to be clinically tested and approved by the regulatory authorities before it can be marketed. It will not have a significant impact on the company's performance in the short term.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.